Potential therapeutic use of melatonin in migraine and other headache disorders

Expert Opinion on Investigational Drugs

Volumn 15, Issue 4, 2006, Pages 367-375

  Peres, Mario F P ^a,b   Masruha, Marcelo R ^a,b   Zukerman, Eliova ^a   Moreira Filho, Carlos Alberto ^a   Cavalheiro, Esper A ^a,b  

^a Instituto Israelita De Pesquisa e Ensino Albert Einstein   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Circadian rhythm; Headache; Headache disorders; Melatonin; Migraine

Indexed keywords

4 AMINOBUTYRIC ACID; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AGOMELATINE; CYTOKINE; DOPAMINE; FREE RADICAL; GLUTAMIC ACID; INDOMETACIN; MELATONIN; MELATONIN DERIVATIVE; MELATONIN RECEPTOR AGONIST; NITRIC OXIDE SYNTHASE; OPIATE; PLACEBO; RAMELTEON; SEROTONIN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CIRCADIAN RHYTHM; CLINICAL TRIAL; CLUSTER HEADACHE; DOPAMINE RELEASE; ENZYME ACTIVITY; HEADACHE; HORMONE BLOOD LEVEL; HUMAN; HYPNIC HEADACHE; MEMBRANE STABILIZATION; MIGRAINE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PINEAL BODY; REVIEW; SINGLE DRUG DOSE;

ANIMALS; HEADACHE DISORDERS; HUMANS; MELATONIN; MIGRAINE DISORDERS;

EID: 33645712464     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.4.367     Document Type: Review

References (94)

1. BIGAL ME, LIPTON RB, STEWART WF: The epidemiology and impact of migraine. Curr. Neurol. Neurosci. Rep. (2004) 4:98-104.
2. HEADACHE CLASSIFICATION COMMITTEE OF THE INTERNATIONAL HEADACHE SOCIETY: Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia (1988) 8:1-96.
3. HEADACHE CLASSIFICATION SUBCOMMITTEE OF THE INTERNATIONAL HEADACHE SOCIETY: The International Classification of Headache Disorders. Cephalalgia (2004) 24:9-160.
4. LIPTON RB, BIGAL ME, STEINER TJ, SILBERSTEIN SD, OLESEN J: Classification of primary headaches. Neurology (2004) 63:427-435.
5. BIGAL ME, LIPTON RB, TEPPER SJ, RAPOPORT AM, SHEFTELL FD: Primary chronic daily headache and its subtypes in adolescents and adults. Neurology (2004) 63:843-847.
6. LIPTON RB, STEWART WF, DIAMOND S, DIAMOND ML, REED M: Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache (2001) 41:646-657.
7. GIFFIN NJ, RUGGIERO L, LIPTON RB et al.: Premonitory symptoms in migraine: an electronic diary study. Neurology (2003) 60:935-940.
8. AMOS JF, FLEMING JB: Clinical description and review of migraine aura without headache. Optometry (2000) 71:372-380.
9. SILBERSTEIN SD, LIPTON RB: Headache epidemiology. Emphasis on migraine. Neurol. Clin. (1996) 14:421-434.
10. LIPTON RB: Comorbidity in migraine-causes and effects. Cephalalgia (1998) 18(Suppl. 22):8-11.
11. MERCANTE JP, PERES MF, MERCANTE JP, PERES MF, GUENDLER V, ZUKERMAN E, BERNIK MA: Depression in chronic migraine: severity and clinical features. Arq. Neuropsiquiatr. (2005) 63:217-220.
12. PERES MF, STILES MA, SIOW HC, SILBERSTEIN SD: Excessive daytime sleepiness in migraine patients. J. Neurol. Neurosurg. Psychiatry (2005) 76:1467-1468.
13. PERES MF, YOUNG WB, KAUP AO, ZUKERMAN E, SILBERSTEIN SD: Fibromyalgia is common in patients with transformed migraine. Neurology (2001) 57:1326-1328.
14. PERES MF: Fibromyalgia, fatigue, and headache disorders. Curr. Neurol. Neurosci. Rep. (2003) 3:97-103.
15. DICHGANS M, FREILINGER T, ECKSTEIN G et al.: Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet (2005) 366:371-377.
16. MOSKOWITZ MA: The neurobiology of vascular head pain. Ann. Neurol. (1984) 16:157-168.
17. BARTSCH T, GOADSBY PJ: The trigeminocervical complex and migraine: current concepts and synthesis. Curr. Pain Headache Rep. (2003) 7:371-376.
18. GOADSBY PJ: Migraine pathophysiology. Headache (2005) 45(Suppl. 1):S14-S24.
19. PERES MF: Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia (2005) 25:403-411.
20. ARENDT J: Importance and relevance of melatonin to human biological rhythms. J. Neuroendocrinol. (2003) 15:427-431.
21. TUREK FW, DUGOVIC C, ZEE PC: Current understanding of the circadian clock and the clinical implications for neurological disorders. Arch. Neurol. (2001) 58:1781-1787.
22. LERNER AB, CASE JD, TAKAHASHI Y: Isolation of melatonin and 5-methoxyindole-3-acetic acid from bovine pineal glands. J. Biol. Chem. (1960) 235:1992-1997.
23. ERLICH SS, APUZZO ML: The pineal gland: anatomy, physiology, and clinical significance. J. Neurosurg. (1985) 63:321-341.
24. REITER RJ: Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr. Rev. (1991) 12:151-180.
25. REITER RJ, CALVO JR, KARBOWNIK M, QI W, TAN DX: Melatonin and its relation to the immune system and inflammation. Ann. NY Acad. Sci. (2000) 917:376-386.
26. DUBBELS R, REITER RJ, KLENKE E et al.: Melatonin in edible plants identified by radioimmunoassay and by high performance liquid chromatography-mass spectrometry. J. Pineal Res. (1995) 18:28-31.
27. MENENDEZ-PELAEZ A, POEGGELER B, REITER RJ, BARLOW-WALDEN L, PABLOS MI, TAN DX: Nuclear localization of melatonin in different mammalian tissues: immunocytochemical and radioimmunoassay evidence. J. Cell Biochem. (1993) 53:373-382.
28. REITER RJ: Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr. Rev. (1991) 12:151-180.
29. MARKEY SP, HIGA S, SHIH M, DANFORTH DN, TAMARKIN L: The correlation between human plasma melatonin levels and urinary 6-hydroxymelatonin excretion. Clin. Chim. Acta (1985) 150:221-225.
30. ORTS RJ, BENSON B: Inhibition effects on serum and pituitary LH by a melatonin-free extract of bovine pineal glands. Life Sci. II (1973) 12:513-519.
31. ZANG LY, COSMA G, GARDNER H, VALLYATHAN V: Scavenging of reactive oxygen species by melatonin. Biochim. Biophys. Acta (1998) 1425:469-477.
32. TAN DX, MANCHESTER LC, HARDELAND R et al.: Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J. Pineal Res. (2003) 34:75-78.
33. REPPERT SM: Melatonin receptors: molecular biology of a new family of G protein-coupled receptors. J. Biol. Rhythms (1997) 12:528-531.
34. GODSON C, REPPERT SM: The Mella melatonin receptor is coupled to parallel signal transduction pathways. Endocrinology (1997) 138:397-404.
35. REPPERT SM, GODSON C, MAHLE CD, WEAVER DR, SLAUGENHAUPT SA, GUSELLA JF: Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc. Natl. Acad. Sci. USA (1995) 92:8734-8738.
36. BUBENIK GA, BLASK DE, BROWN GM et al.: Prospects of the clinical utilization of melatonin. Biol. Signals Recept. (1998) 7:195-219.
37. GORDIJN MC, BEERSMA DG, KORTE HJ, VAN DEN HOOFDAKKER RH: Testing the hypothesis of a circadian phase disturbance underlying depressive mood in nonseasonal depression. J. Biol. Rhythms (1998) 13:132-147.
38. RODENBECK A, HUETHER G, RUTHER E, HAJAK G: Nocturnal melatonin secretion and its modification by treatment in patients with sleep disorders. Adv. Exp. Med. Biol. (1999) 467:89-93.
39. CAJOCHEN C, KRAUCHI K, WIRZ-JUSTICE A: Role of melatonin in the regulation of human circadian rhythms and sleep. J. Neuroendocrinol. (2003) 15:432-437.
40. CHECKLEY SA, MURPHY DG, ABBAS M et al.: Melatonin rhythms in seasonal affective disorder. Br. J. Psychiatry (1993) 163:332-337.
41. ZEE PC: Neurological disorders associated with disturbed sleep and circadian rhythms. In: Regulation of Sleep and Circadian Rhythms, Turek FW ZP (Ed.), Marcel Dekker, Inc., New York, USA (1999):557-596.
42. CHUANG JI, MOHAN N, MELTZ ML, REITER RJ: Effect of melatonin on NF-κB DNA-binding activity in the rat spleen. Cell Biol. Int. (1996) 20:687-692.
43. SHAIKH AY, XU J, WU Y, HE L, HSU CY: Melatonin protects bovine cerebral endothelial cells from hyperoxia-induced DNA damage and death. Neurosci. Lett. (1997) 229:193-197.
44. BETTAHI I, POZO D, OSUNA C, REITER RJ, ACUNA-CASTROVIEJO D, GUERRERO JM: Melatonin reduces nitric oxide synthase activity in rat hypothalamus. J. Pineal Res. (1996) 20:205-210.
45. GARCIA JJ, REITER RJ, GUERRERO JM et al.: Melatonin prevents changes in microsomal membrane fluidity during induced lipid peroxidation. FEBS Lett. (1997) 408:297-300.
46. ZISAPEL N: Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. Cell Mol. Neurobiol. (2001) 21:605-616.
47. PEROUTKA SJ: Dopamine and migraine. Neurology (1997) 49:650-656.
48. RAMADAN NM: The link between glutamate and migraine. CNS Spectr. (2003) 8:446-449.
49. WANG F, LI JC, WU CF, YANG JY, XU F, PENG F: Hypnotic activity of melatonin: involvement of semicarbazide hydrochloride, blocker of synthetic enzyme for GABA. Acta Pharmacol. Sin. (2002) 23:860-864.
50. A receptor-mediated current in cultured chick spinal cord neurons. Neurosci. Lett. (1999) 260:177-180.
51. ESPINAR A, GARCIA-OLIVA A, ISORNA EM, QUESADA A, PRADA FA, GUERRERO JM: Neuroprotection by melatonin from glutamate-induced excitotoxicity during development of the cerebellum in the chick embryo. J. Pineal Res. (2000) 28:81-88.
52. ZHANG QZ, GONG YS, ZHANG JT: Antagonistic effects of melatonin on glutamate release and neurotoxicity in cerebral cortex. Zhongguo Yao Li Xue Bao (1999) 20:829-834.
53. EBADI M, GOVITRAPONG P, PHANSUWAN-PUJITO P, NELSON F, REITER RJ: Pineal opioid receptors and analgesic action of melatonin. J. Pineal Res. (1998) 24:193-200.
54. SAVASKAN E, OLIVIERI G, BRYDON L et al.: Cerebrovascular melatonin MT1-receptor alterations in patients with Alzheimer's disease. Neurosci. Lett. (2001) 308:9-12.
55. 3H]serotonin release in the rat hippocampus: effects of circadian rhythm. J. Neuroendocrinol, (2002) 14:194-199.
56. GALEGO JC, CIPULLO JP, CORDEIRO JA, TOGNOLA WA: Clinical features of episodic migraine and transformed migraine: a comparative study. Arq. Neuropsiquiatr. (2002) 60:912-916.
57. PAIVA T, BATISTA A, MARTINS P, MARTINS A: The relationship between headaches and sleep disturbances. Headache (1995) 35:590-596.
58. SILBERSTEIN SD: The role of sex hormones in headache. Neurology (1992) 42:37-42.
59. GRANELLA F, SANCES G, ZANFERRARI C, COSTA A, MARTIGNONI E, MANZON1 GC: Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache (1993) 33:385-389.
60. MEDINA JL, DIAMOND S: Cyclical migraine. Arch. Neurol. (1981) 38:343-344.
61. YOUNG WB, PERES MF, ROZEN TD: Modular headache theory. Cephalalgia (2001) 21:842-849.
62. PERES MF, STILES MA, SIOW HC, DOGRAMJI K, SILBERSTEIN SD, CIPOLLA-NETO J: Chronobiological features in episodic and chronic migraine. Cephalalgia (2003) 23:590-591.
63. CLAUSTRAT B, LOISY C, BRUN J, BEORCHIA S, ARNAUD JL, CHAZOT G: Nocturnal plasma melatonin levels in migraine: a preliminary report. Headache (1989) 29:242-245.
64. MURIALDO G, FONZI S, COSTELLI P et al.: Urinary melatonin excretion throughout the ovarian cycle in menstrually related migraine. Cephalalgia (1994) 14:205-209.
65. BRUN J, CLAUSTRAT B, SADDIER P, CHAZOT G: Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. Cephalalgia (1995) 15:136-139.
66. PERES MF, SANCHEZ DR, SEABRA ML et al.: Hypothalamic involvement in chronic migraine. J. Neurol. Neurosurg. Psychiatry (2001) 71:747-751.
67. CLAUSTRAT B, BRUN J, GEOFFRIAU M, ZAIDAN R, MALLO C, CHAZOT G: Nocturnal plasma melatonin profile and melatonin kinetics during infusion in status migrainosus. Cephalalgia (1997) 17:511-517.
68. NACTEGAAL JE, LAURANT MW, KERKHOF GA, SMITS MG, VAN DER MEER YG, COENEN AM: Effects of melatonin on the quality of life in patients with delayed sleep phase syndrome. J. Psychosom. Res. (2000) 48:45-50.
69. SANDYK R: The influence of the pineal gland on migraine and cluster headaches and effects of treatment with pico Tesla magnetic fields. Int. J. Neurosci. (1992) 67:145-171.
70. PERES MF, ZUKERMAN E, DA CUNHA TF, MOREIRA FR, CIPOLLA-NETO J: Melatonin, 3 mg, is effective for migraine prevention. Neurology (2004) 63:757.
71. MAY A, BAHRA A, BUCHEL C, FRACKOWIAK RS, GOADSBY PJ: Hypothalamic activation in cluster headache attacks. Lancet (1998) 352:275-278.
72. CHAZOT G, CLAUSTRAT B, BRUN J, JORDAN D, SASSOLAS G, SCHOTT B: A chronobiological study of melatonin, cortisol growth hormone and prolactin secretion in cluster headache. Cephalalgia (1984) 4:213-220.
73. WALDENLIND E, GUSTAFSSON SA, EKBOM K, WETTERBERG L: Circadian secretion of cortisol and melatonin in cluster headache during active cluster periods and remission. J. Neurol. Neurosurg. Psychiatry (1987) 50:207-213.
74. WALDENLIND E, EKBOM K, WETTERBERG L et al.: Lowered circannual urinary melatonin concentrations in episodic cluster headache. Cephalalgia (1994) 14:199-204.
75. LEONE M, LUCINI V, D'AMICO D et al.: Twenty-four-hour melatonin and cortisol plasma levels in relation to timing of cluster headache. Cephalalgia (1995) 15:224-229.
76. BLAU JN, ENGEL HO: Anew cluster headache precipitant: increased body heat. Lancet (1999) 354:1001-1002.
77. PERES MF, SEABRA ML, ZUKERMAN E, TUFIK S: Cluster headache and melatonin. Lancet (2000) 355:147.
78. LEONE M, D'AMICO D, MOSCHIANO F, FRASCHINI F, BUSSONE G: Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia (1996) 16:494-496.
79. PERES MF, ROZEN TD: Melatonin in the preventive treatment of chronic cluster headache. Cephalalgia (2001) 21:993-995.
80. NAGTEGAAL JE, SMITS MG, SWART AC, KERKHOF GA, VAN DER MEER YG: Melatonin-responsive headache in delayed sleep phase syndrome: preliminary 92. observations. Headache (1998) 38:303-307.
81. DODICK DW, JONES JM, CAPOBIANCO DJ: Hypnic headache: another indomethacin-responsive headache syndrome? Headache (2000) 40:830-835.
82. DODICK DW, EROSS EJ, PARISH JM: Clinical, anatomical, and physiologic relationship between sleep and headache. Headache (2003) 43:282-292.
83. CAPO G, ESPOSITO A: Hypnic headache: a new Italian case with a good response to pizotifene and melatonin. Cephalalgia (2001) 21:505-506.
84. MARTINS IP, GOUVEIA RG: Hypnic headache and travel across time zones: a case report. Cephalalgia (2001) 21:928-931.
85. PERES MF, STILES MA, OSHINSKY M, ROZEN TD: Remitting form of hemicrania continua with seasonal pattern. Headache (2001) 41:592-594.
86. ROZEN TD: Melatonin as treatment for indomethacin-responsive headache syndromes. Cephalalgia (2003) 23:734-735.
87. ROZEN TD: Melatonin as treatment for idiopathic stabbing headache. Neurology (2003) 61:865-866.
88. ATKINSON G, DRUST B, REILLY T, WATERHOUSE J: The relevance of melatonin to sports medicine and science. Sports Med. (2003) 33:809-831.
89. PRINGSHEIM T, MAGNOUX E, DOBSON CF, HAMEL E, AUBE M: Melatonin as adjunctive therapy in the prophylaxis of cluster headache: a pilot study. Headache (2002) 42(8):787-792.
90. PUCCI E, MATOZZO F, SANDRINI G, COSTA A, CITTERIO A, NAPPI G: Shift work and headache: observations in a group of hospital workers. Cephalalgia (2003) 23:605.
91. HO KH, ONG BK: A community-based study of headache diagnosis and prevalence in Singapore. Cephalalgia (2003) 23:6-13.
92. DE VRIES MW, PEETERS FP: Melatonin as a therapeutic agent in the treatment of sleep disturbance in depression. J. Nerv. Ment. Dis. (1997) 185:201-202.
93. Ramelteon (Rozerem) for insomnia. Med. Lett. Drugs Ther. (2005) 47:89-91.
94. KENNEDY SH, EMSLEY R: Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur. Neuropsychopharmacol. (2005).